EGFR and glioblastoma: Monoclonal antibodies such as cetuximab or nimotuzumab [16,17,18], small tyrosine kinase inhibitors such as erlotinib [19,20], lapatinib [21] and vandetinib [22] and even immunotherapic approaches such as anti-EGFR vaccination presented limited results when administered to GBM patients [23,24].